GLPwatch

Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

NCT06409130 · Completed

Last updated 2026-05-28

This clinical trial is testing the effects of different doses of the medications NNC0194-0499, cagrilintide, and semaglutide—alone or combined—on liver damage and alcohol use in adults with alcohol-related liver disease.

Status Completed The study has finished.
Phase Phase 2 Tests whether it works and watches safety in a moderate group.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 270 people
Who can join Ages 18+ · all sexes
Timeline Started 2024-05 · est. completion 2026-01
Where 102 sites · Australia, Bulgaria, Canada, Czechia, Denmark, France, Germany, Greece, Italy, Japan, Netherlands, Poland, Spain, United States

What this study is testing ClinicalTrials.gov NCT06409130 ↗

Description as written by the study sponsor.

The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or ''dummy" medicine in different treatment combinations. Which treatment participants get is decided by chance. The study will last for about 39 weeks.

Treatments tested

Main thing measuredChange in Enhanced Liver Fibrosis (ELF)
SponsorNovo Nordisk A/S
Conditions studiedAlcohol-related Liver Disease
GLP-1 drugs semaglutide, cagrilintide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06409130 ↗